Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GNAO1 | P09471 | 4/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | CXCR4 | P61073 | 3/20 | 0.41 |
| ▸ | GNAI3 | P08754 | 3/20 | 0.41 |
| ▸ | GNAI1 | P63096 | 3/20 | 0.41 |
| ▸ | RAD52 | P43351 | 1/20 | 0.39 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.37 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.37 |
| ▸ | ITGB3 | P05106 | 2/20 | 0.36 |
| ▸ | ITGA2B | P08514 | 2/20 | 0.36 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL42348 | 0.98 | GNAO1 (0.49) | GNAO1CYP1A2CXCR4GNAI3GNAI1 | |
| Hydrochloric Acid SCHEMBL6150599 | 0.98 | GNAO1 (0.53) | GNAO1CYP1A2CXCR4GNAI3GNAI1 | |
| Hydrochloric Acid SCHEMBL4424002 | 0.96 | GNAO1 (0.51) | GNAO1CYP1A2CXCR4GNAI3GNAI1 | |
| SCHEMBL3440711 | 0.96 | GNAO1 (0.50) | GNAO1CYP1A2CXCR4GNAI3GNAI1 | |
| SCHEMBL13660827 | 0.94 | GNAO1 (0.46) | GNAO1CYP1A2CXCR4GNAI3GNAI1 | |
| SCHEMBL13661478 | 0.92 | GNAO1 (0.45) | GNAO1CYP1A2CXCR4GNAI3GNAI1 | |
| SCHEMBL12843901 | 0.89 | GNAO1 (0.51) | GNAO1CXCR4GNAI3GNAI1RAD52 | |
| SCHEMBL5848080 | 0.88 | GNAO1 (0.56) | GNAO1CXCR4GNAI3GNAI1RAD52 | |
| SCHEMBL13660823 | 0.88 | CHRM5 (0.50) | GNAO1CYP1A2GNAI3GNAI1RAD52 | |
| Hydrochloric Acid SCHEMBL27752774 | 0.87 | GNAO1 (0.54) | GNAO1CXCR4GNAI3GNAI1RAD52 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 109 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3193604-B1 | SUBSTITUTED N-(PYRROLIDIN-3-YL)ISOXAZOLE-3-CARBOXAMIDE COMPOUNDS | EPIZYME INC (US) | 2021-06-16 | — | — | EP | disclosed |
| CN-104968345-B | 1, 5-naphthyridine derivatives and ME L K inhibitors containing 1, 5-naphthyridine derivatives | 肿瘤疗法科学股份有限公司 | 2018-05-08 | — | — | CN | disclosed |
| EP-2753329-B1 | 1,5-NAPHTHYRIDINE DERIVATIVES AS MELK INHIBITORS | ONCOTHERAPY SCIENCE INC (JP) | 2017-08-09 | — | — | EP | disclosed |
| US-9345709-B2 | 1,5-naphthyridine derivatives and MELK inhibitors containing the same | ONCOTHERAPY SCIENCE, INC. (JP) | 2016-05-24 | — | — | US | disclosed |
| US-20150328225-A1 | 1,5-NAPHTHYRIDINE DERIVATIVES AND MELK INHIBITORS CONTAINING THE SAME | ONCOTHERAPY SCIENCE, INC. (JP) | 2015-11-19 | — | — | US | disclosed |
| CN-104968345-A | 1, 5-naphthyridine derivatives and MELK inhibitors containing 1, 5-naphthyridine derivatives | ONCOTHERAPY SCIENCE INC | 2015-10-07 | — | — | CN | disclosed |
| US-9067937-B2 | 1,5-naphthyridine derivatives and MELK inhibitors containing the same | ONCOTHERAPY SCIENCE, INC. (JP) | 2015-06-30 | — | — | US | disclosed |
| US-20150005302-A1 | 1,5-NAPHTHYRIDINE DERIVATIVES AND MELK INHIBITORS CONTAINING THE SAME | ONCOTHERAPY SCIENCE, INC. (JP) | 2015-01-01 | — | — | US | disclosed |
| US-8907098-B2 | Inhibitors of sphingosine kinase | MERCK PATENT GMBH (DE) | 2014-12-09 | — | — | US | disclosed |
| EP-2668177-B1 | SUBSTITUTED PYRIDINYL-PYRIMIDINES AND THEIR USE AS MEDICAMENTS | BOEHRINGER INGELHEIM INT (DE) | 2014-10-22 | — | — | EP | disclosed |
| US-20060178360-A1 | Benzenesulphonamide derivatives, method for production and use thereof for treatment of pain | LABORATOIRES FOURNIER S.A. (FR) | 2006-08-10 | — | — | US | disclosed |
| WO-2006023400-A2 | CHEMICAL COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2006-03-02 | — | — | WO | disclosed |
| EP-1606288-A1 | BENZENESULPHONAMIDE DERIVATIVES, METHOD FOR PRODUCTION AND USE THEREOF FOR TREATMENT OF PAIN | LABORATOIRES FOURNIER S.A. (FR) | 2005-12-21 | — | — | EP | disclosed |
| US-6809199-B2 | ANTIINFLAMMATORY AGENTS; RHEUMATIC DISEASES | MERCK & CO., INC. | 2004-10-26 | — | — | US | disclosed |
| WO-2004087700-A1 | BENZENESULPHONAMIDE DERIVATIVES, METHOD FOR PRODUCTION AND USE THEREOF FOR TREATMENT OF PAIN | LABORATOIRES FOURNIER S.A. (FR) | 2004-10-14 | — | — | WO | disclosed |
| EP-1345603-A4 | (HALO-BENZO CARBONYL)HETEROCYCLO FUSED PHENYL P38 KINASE INHIBITING AGENTS | MERCK & CO INC (US) | 2004-09-08 | — | — | EP | disclosed |
| EP-1345603-A1 | (HALO-BENZO CARBONYL)HETEROCYCLO FUSED PHENYL P38 KINASE INHIBITING AGENTS | Merck & Co., Inc. (US) | 2003-09-24 | — | — | EP | disclosed |
| WO-2002058695-A9 | (HALO-BENZO CARBONYL)HETEROCYCLO FUSED PHENYL P38 KINASE INHIBITING AGENTS | MERCK & CO INC (US) | 2003-09-12 | — | — | WO | disclosed |
| US-20030092712-A1 | (Halo-benzo carbonyl)heterocyclo fused phenyl p38 kinase inhibiting agents | MERCK SHARP & DOHME CORP. | 2003-05-15 | — | — | US | disclosed |
| WO-2002058695-A1 | (HALO-BENZO CARBONYL)HETEROCYCLO FUSED PHENYL P38 KINASE INHIBITING AGENTS | MERCK & CO., INC. (US) | 2002-08-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150328225-A1 | 1,5-NAPHTHYRIDINE DERIVATIVES AND MELK INHIBITORS CONTAINING THE SAME | MELK, NEK1, NEK5 | GNAO1 3118/4885CYP1A2 3078/4885CXCR4 4320/4885 |
| US-20060178360-A1 | Benzenesulphonamide derivatives, method for production and use thereof for treatment of pain | LTB4R2, BDKRB2, TBXA2R | GNAO1 1547/4885CYP1A2 78/4885CXCR4 296/4885 |
| US-20150005302-A1 | 1,5-NAPHTHYRIDINE DERIVATIVES AND MELK INHIBITORS CONTAINING THE SAME | MELK, NEK1, NEK5 | GNAO1 3118/4885CYP1A2 3078/4885CXCR4 4320/4885 |
| US-20030092712-A1 | (Halo-benzo carbonyl)heterocyclo fused phenyl p38 kinase inhibiting agents | MAPK1, MAPK7, MAPKAPK2 | GNAO1 839/4885CYP1A2 1342/4885CXCR4 1487/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.